|Articles|June 1, 2022
Meeting Regulatory Needs in the Characterization of Lipid Nanoparticles (LNPs) for RNA Delivery via FFF-MALS
Author(s)Wyatt
The white paper discusses a validated FFF-MALS method in line with technical specification ISO/TS 21362 for the analysis of lipid-based nanoparticles (LNPs).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5